The gene for dihydrofolate reductase of Mycobacterium tuberculosis was amplified by polymerase chain reaction (PCR) from M. tuberculosis H37Rv strain genomic DNA. The protein was expressed in inclusion bodies in high yield in Escherichia coli under the control of the T7 promoter. Active enzyme was obtained by refolding from guanidine HCl and after a single chromatography step the sample was s 99% homogeneous with a specific activity of V15.5 Wmol min 31 mg 31 . Mass spectrometry analysis confirmed the expected mass of 17.6 kDa. Gel filtration of the enzyme indicated that it was a monomer. Steady-state kinetic parameters were determined and the effect of pH and KCl on the enzyme examined. Methotrexate and trimethoprim inhibited the enzyme.
Introduction
Mycobacterium tuberculosis causes tuberculosis, a disease of worldwide signi¢cance, and is an opportunistic pathogen that infects AIDS patients [1] . New drugs are urgently needed to treat this disease, as this mycobacterium is becoming increasingly resistant to existing drugs used to treat these infections. The enzyme dihydrofolate reductase (DHFR) has been a drug-design target for decades [2, 3] . DHFR (EC 1.5.1.3) is found in the cells of all organisms where it maintains the intracellular level of reduced folates. Tetrahydrofolate is an essential cofactor for a number of enzymes necessary for the synthesis of DNA, RNA, and proteins. Inhibitors of DHFR reduce the intracellular level of tetrahydrofolate resulting in aberrant cellular metabolism. In rapidly dividing cells, the inhibition of DNA synthesis leads to cell death. A detailed comparison of the M. tuberculosis and human enzyme should provide needed data for the design of drugs with high potency as well as selectivity for e¡ective therapy.
Materials and methods

Cloning, expression, and puri¢cation of
M. tuberculosis and human DHFR M. tuberculosis strain H37Rv genomic DNA was prepared as previously described [4] . Coding sequence for DHFR (dfrA) was ampli¢ed from M. tuberculosis strain H37Rv chromosomal DNA by polymerase chain reaction (PCR) using the following primers designed according to the published genome sequence (GenBank accession number NC_000962): forward primer 5P-GAC GCG TGT GCA TAT GGT GGG GCT GAT CTG-3P and reverse primer 5P-GCG ATG AGG ATC CGC GGC GCT CAT GAG CGG-3P, containing NdeI and BamHI restriction sites, respectively. Ampli¢ed fragment was cleaned using the QIAquick PCR puri¢cation kit (Qiagen). Both the ampli¢ed dfrA gene and pET11a expression vector (Novagen) were then digested with NdeI and BamHI, puri¢ed on a 0.7% agarose gel, eluted, and ligated together, using T4 DNA ligase overnight at 15 ‡C. The resulting construct was sequenced to con¢rm that the dfrA gene was in the proper con¢guration for expression, under control of the pET11a T7 promoter, and that no mutations had occurred during the PCR ampli¢cation. After propagation in Escherichia coli strain DH5K, the construct was puri¢ed and transferred into E. coli strain BL21 STAR (Invitrogen) for expression.
The dfrA gene was expressed from the pET11a T7 promoter as follows : E. coli cells were grown in Luria^Bertani (LB) medium at 37 ‡C until optical density (OD 600 ) reached 0.4^0.5. Induction was performed by addition of 1 mM isopropyl-L-thiogalactopyranoside (IPTG), and cells were grown for three more hours at 37 ‡C to reach an OD of 1.5. Cells were centrifuged, washed with cold phosphate-bu¡ered saline (PBS) and the pellet frozen at 380 ‡C. Pilot experiments using B-PER 0 (Pierce) demonstrated that all of the recombinant protein was in the inclusion bodies, i.e. insoluble in this detergent system.
The M. tuberculosis DHFR was puri¢ed using the following protocol. All procedures were performed at 4 ‡C except as indicated. The pellet from 1 l of E. coli culture was resuspended in 40 ml of 50 mM Tris^HCl, pH 8.0, 100 mM NaCl, 1 mM ethylenediamine tetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), and 10 Wg ml 31 lysozyme. After agitation at room temperature for 15 min, the sample was extracted by two passes through a French press at 15 000^20 000 lb/in 2 . The inclusion bodies were collected by centrifugation at 15 000Ug for 20 min. The pellet was washed twice in bu¡er containing 1 M guanidine HCl and dissolved in bu¡er containing 4 M guanidine HCl. After centrifugation to remove insoluble material, the DHFR was refolded overnight by dropwise dilution into 1.5 l of 50 mM potassium phosphate, pH 7.0, 2 mM DTT, and 2 mM EDTA. After centrifugation to remove insoluble material, the supernatant was loaded slowly onto a methotrexate-Sepharose column equilibrated in 10 mM potassium phosphate, pH 7.0. The column was washed with 200 mM potassium phosphate, pH 6.0, 1 M KCl, 1 mM DTT, and 1 mM EDTA. Enzyme was eluted using 50 mM Tris^HCl, pH 8.0, 1 M KCl, 1 mM DTT, 1 mM EDTA, and 2 mM dihydrofolate (DHF). Bu¡er exchange was accomplished using a Sephadex G-25 column equilibrated with 20 mM maintenance electrolyte solution (MES), pH 6.0, 100 mM KCl, 1 mM DTT, 0.1 mM EDTA, and 1.5 mM NaN 3 . The enzyme was stable for at least two years at 380 ‡C in 10% glycerol.
The cDNA for human DHFR (plasmid pDFR ; [5] ) was obtained from Prof. Andre ¤ Rosowsky, Dana Farber Cancer Institute, Boston, MA, USA. In previous work pDFR provided us with only moderate quantities of human DHFR so the cDNA was subcloned into pET11a. The protein was expressed in E. coli BL21(DE3) upon induction with 1 mM IPTG at 37 ‡C. Recombinant human DHFR was puri¢ed to homogeneity (in essence following [5] ) by lysis (French press), methotrexate-agarose a⁄nity chromatography (elution with folate), anion exchange chromatography (MonoQ), and gel ¢ltration. The typical yield from 1 l of E. coli culture was 23 mg of recombinant human DHFR, with a speci¢c activity of V16 Wmol min 31 mg 31 .
Enzyme assay
DHFR activity was measured spectrophotometrically at 37 ‡C. Standard assay conditions were 50 mM KPO 4 , pH 7.3, 5 mM L-mercaptoethanol, and 60 WM reduced nicotinamide adenine dinucleotide phosphate (NADPH) and the reaction was started after a 3 min incubation by the addition of 45 WM DHF. The molar extinction coe⁄cient change for the reaction at 340 nm is 12 270 M 31 cm 31 [6] . Steady-state kinetics for the determination of K m values were performed by a computer program which uses nonlinear least-square analysis [7] to generate K m values with standard errors. The e¡ect of pH on enzyme activity was determined using a constant ionic strength system of 150 mM that also contained 5 mM L-mercaptoethanol (http:// www.bi.umist.ac.uk/users/mjfrbn/bu¡ers/makebuf.asp). M. tuberculosis DHFR was readily puri¢ed to apparent homogeneity from inclusion bodies. The ¢nal yield of puri¢ed M. tuberculosis DHFR at pH 7.0 and 37 ‡C was 10 mg from 1 l of E. coli culture with a speci¢c activity of V15.5 Wmol min 31 mg 31 . This enzyme had a speci¢c activity 3.6 times higher than that of enzyme puri¢ed from a soluble fraction [8] , indicating that the renaturation step produced correctly refolded enzyme. Signi¢cantly, the renatured enzyme gives crystals identical to the published ones (Rongbao Li, personal communication). Spectrometric analysis (matrix-assisted laser desorption/ionizationtime of £ight (MALDI-TOF)) con¢rmed that the protein had the correct mass (observed, 17 643 Da; calculated, 17 641 Da). N-terminal sequencing con¢rmed the expected sequence of MVGLIWAQAT. Analytical gel ¢ltration showed that the protein eluted as a monomer at V19 000 Da. DHFRs from other species, including the closely related Mycobacterium smegmatis [9] , are monomers. Fig. 1 gives the amino acid sequence for M. tuberculosis DHFR and compares it to the human enzyme. The sequence alignment between M. tuberculosis and human DHFR shows only V26% identity; however, the sequence identity in the ligand binding sites is much higher at V55% [8] .
The kinetic properties of M. tuberculosis and human DHFR were investigated. Both enzymes were assayed in constant ionic strength bu¡ers ranging from pH 5 to 9 (Fig. 2) . M. tuberculosis DHFR was most active at the lower pH values ; the activity at pH 9 was 8% of that at pH 5. The enzyme from Mycobacterium phlei has its maximum activity at pH 7 [10] . Human DHFR was more active at the higher pHs and the pH e¡ect was less dramatic; activity changed by V50% between pH 5 and 9. For both enzymes this e¡ect was on activity and not on stability. When M. tuberculosis DHFR was incubated in bu¡er at pH 5 or 9 for either 5 or 20 min and then assayed at pH 7, there was no e¡ect when compared to enzyme incubated at pH 7. There was less than a 12% drop in activity for human. Our results di¡er from previously published data on human DHFR where a general decrease in activity was seen from pH 4 to 9 with two or three maxima [11^13]. The conditions of our assay di¡ered in several respects from that of the other investigators, primarily in that we were careful to maintain constant ionic strength throughout the pH range.
Chaotropic agents such as KCl are known to activate DHFRs [5, 11, 14] . There was a steady increase in M. tuberculosis DHFR activity from 0 to 1 M KCl (Fig. 3) . At pH 7.3 there was a 3.6-fold increase and at pH 6.0 the increase was 5.6-fold. The maximum activity for human DHFR was obtained at 0.5 M KCl similar to that seen by others [5, 12, 13] . Wright and collaborators [14] found that KCl a¡ected the activity of E. coli and Haloferax volcanii DHFR by several mechanisms. KCl altered the £exibility of the enzyme thus altering the enzyme's ability to catalyze the substrates, changed substrate a⁄nity for the enzyme, and had a pronounced e¡ect on the global folding or unfolding of the protein. Our work does not let us explore the mechanism of enzyme activation by KCl observed for M. tuberculosis DHFR.
Michaelis constants for NADPH and DHF were obtained for both enzymes by varying each substrate in the presence of a ¢xed saturating concentration of the other ( Table 1 ). The K m values for both enzymes were very similar. For DHF, M. tuberculosis DHFR had a K m of 4.5 þ 0.6 WM and human had a K m of 2.8 þ 0.5 WM. For NADPH, the K m values were 4.2 þ 0.6 and 9.1 þ 0.9 WM for M. tuberculosis and human, respectively. Reported kinetic constants (K m ) for human DHFR have varied from a low value of 0.022 WM for DHF and 0.26 WM for [12] . Our values are slightly higher than these. Such a wide variation probably indicates that these constants are highly dependent on assay conditions. Alternatively, the di¡erences could be due to the source of the enzyme and its purity. Kinetic constants from two other mycobacteria have been reported [9, 10] and the three mycobacteria have a similar a⁄nity for DHF. The classical DHFR inhibitors trimethoprim and methotrexate were evaluated for their ability to inhibit M. tuberculosis DHFR ( Table 2) . As expected, methotrexate was the most potent DHFR inhibitor with IC 50 values in the nM range. However, the compound is even more potent against the human enzyme than the M. tuberculosis enzyme.
The speci¢c activity and substrate K m values of the authentic M. tuberculosis DHFR are typical of those found in other organisms. M. phlei DHFR with a speci¢c activity of 50 Wmol min 31 mg 31 is slightly more active than the enzyme from M. tuberculosis [10] . Both enzymes have similar binding a⁄nities for DHF (K m is 4.5 WM for M. tuberculosis vs. 8.6 WM for M. phlei); both are more sensitive to methotrexate than trimethoprim. In fact, the kinetic constants and relative potency for the standard DHFR inhibitors for the mycobacterial enzymes are very similar to those of the human enzyme. The most obvious di¡erences between the M. tuberculosis and human DHFRs occur in their pH and chaotropic activation pro¢les. The dramatic increase in activity as pH is lowered appears to be unique for DHFRs and may be an important point to consider in designing speci¢c inhibitors of the bacterial enzyme. The di¡erences in KCl e¡ect point to di¡erences in loop mobility between the enzymes arguing that more needs to be taken into consideration than is o¡ered by a static picture of the enzyme active sites.
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